Bimatoprost in the treatment of eyelash hypotrichosis

Simon K Law, Simon K Law

Abstract

Eyelashes hypotrichosis is a condition indicated by an inadequate amount of eyelashes. Hypertrichosis of eyelashes, characterized by excessive eyelash growth, is a regular phenomenon associated with ophthalmic prostaglandin and prostamide analogs. Recently, the US Food and Drug Administration approved Latisse((R)) (bimatoprost 0.03% solution), identical to the ophthalmic solution for glaucoma treatment, for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes. When prostaglandin and prostamide analogs interact with the prostanoid receptors in the hair follicle, this most likely stimulates the resting follicles (telogen phase) to growing follicles (anagen phase). Prostaglandin and prostamide analogs may also prolong the anagen phase of eyelashes, leading to an increase of eyelash length. Although bimatoprost is effective in promoting increased growth of healthy eyelashes and adnexal hairs, its effectiveness in patients with eyelash alopecia areata is debatable and its protective effect is not yet studied in patients with eyelash loss secondary to radiation or chemotherapy. Bimatoprost is generally safe when applied to the base of the eyelashes at the lid margin with minimum side effects. However, other ocular or systemic side effects associated with ophthalmic prostaglandin and prostamide analogs may occur when instilled on the surface of the eye, and patients must be informed and monitored.

Keywords: Latisse; bimatoprost; eyelash; hypotrichosis; prostaglandin; prostamide.

References

    1. International society of hair restoration surgery. Eyelash transplantation: Who, Why and How. [Accessed Nov 30, 2009]. .
    1. Woodson SA. Latisse: empirical discovery yields treatment for sparse eyelashes. Nurs Womens Health. 2009;13:243–248.
    1. Pucci N, Novembre E, Lombardi E, et al. Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis. Pediatrics. 2005;115:1542–1555.
    1. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544–547.
    1. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997;115:1206–1208.
    1. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110–121.
    1. Noecker RS, Dirks MS, Choplin NT, et al. Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and lantanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63.
    1. Parrish RK, Palmberg P, Sheu WP XLT Study Group. A comparison of lantaoprost, bimatoprost, and travaprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703.
    1. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262–266.
    1. Liotet S, Riera M, Nguyen H. Les cils. Physiologie, structure, pathologie. Arch Ophthalmol. 1977;37:697–708.
    1. Na JI, Kwon OS, Kim BK, et al. Ethnic characteristics of eyelashes: a comparative analysis in Asian and Caucasian females. Br J Dermatol. 2006;155:1170–1176.
    1. Montagna W, Ford DM. Histology and cytochemistry of human skin. 3. The eyelid. Arch Dermatol. 1969;100:328–335.
    1. Thibaut S, De Becker E, Calsey L, et al. Human eyelash characterization. Br J Dermatol. 1 Sep 2009; [Epub ahead of print]
    1. Bartosová L. Biology of hair growth. Curr Probl Dermatol. 1984;12:1–58.
    1. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 1):S185–S202.
    1. Katz M, Wheeler KE, Radowsky M, Gordon W. Assessment of rate of hair growth using a simple trichometer. Med Biol Eng Comput. 1979;17:333–336.
    1. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363–392.
    1. Elder MJ. Anatomy and physiology of eyelash follicles: relevance to lash ablation procedures. Ophthal Plast Reconstu Surg. 1997;13:21–25.
    1. Bläuer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P. Location of androgen receptor in human skin. J Invest Dermatol. 1991;97:264–268.
    1. Randall VA, Hibberts NA, Thornton MJ, et al. The hair follicle: a paradoxical androgen target organ. Horm Res. 2000;54:243–250.
    1. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan) Surv Ophthalmol. 2001;45 (Suppl 4):S337–S345.
    1. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024) J Pharmacol Exp Ther. 2003;305:772–785.
    1. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol. 2008;20 (Suppl 1):1–9.
    1. Alpini G, Demorrow S. Changes in the endocannabinoid system may give insight into new and effective treatments for cancer. Vitam Horm. 2009;81:469–485.
    1. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol. 2006;160:1–24.
    1. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. 2008;153:410–419.
    1. Liang Y, Woodward DF, Guzman VM, et al. Identif ication and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154:1079–1093.
    1. Colombe L, Vindios A, Michelet JF, Bernard BA. Prostaglandin metabolism in human hair follicle. Exp Dermatol. 2007;16:762–769.
    1. Colombe L, Michelet JF, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol. 2008;17:63–72.
    1. Torii E, Segi E, Sugimoto Y, et al. Expression of prostaglandin E92 receptor subtypes in mouse hair follicles. Biochem Biophys Res Comm. 2002;290:696–700.
    1. Rosenigk HH., Jr New topical agents for hair growth. Clin Dermatol. 1988;6:119–121.
    1. Meyer HC. Alopecia associated with ibuprofen. JAMA. 1979;242:142.
    1. Pillans PI, Woods DJ. Drug-associated alopecia. Int J Dermatol. 1995;34:149–158.
    1. Michelet JF, Commo S, Billoni N, Mahe YF, Bernard BA. Activation of ytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108:205–209.
    1. Stjernschantz JW. From PGF (2alpha)-isopropyl ester to lantaoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134–1145.
    1. Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2α and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005;14:323–328.
    1. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macaque: a pilot study. Acta Derm Venereol. 2002;82:7–12.
    1. Burnett JW, Harvey VM. Circumscribed palmar or plantar hypokeratosis: report of two additional cases. J Am Acad Dermatol. 2004;51:843–844.
    1. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341:491–497.
    1. Demitsu T, Manabe M, Harima N, Sugiyama T, Yoneda K, Yamada N. Hypertrichosis induced by lantanoprost. J Am Acad Dermatol. 2001;44:721–723.
    1. Inouye K, Wakakura M, Inoue J, Matsuo H, Hara T, Tomita G. Adverse reaction after use of latanoprost in Japanese glaucoma patients. Nippon Ganka Gakkai Zasshi. 2006;110:581–587.
    1. Elgin U, Batman A, Becker N, Iihan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol. 2006;16:247–250.
    1. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472–484.
    1. Sherwood M, Brandt J Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45 (Suppl 4):S361–S368.
    1. Brandt JD, VanDenburgh AM, Chen K, et al. Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023–1031.
    1. Food and Drug Administration, Division of Anti-infective and Ophthalmology Products Advisory Committee. Briefing information: bimatoprost ophthalmic solution for the treatment of hypotrichosis of the eyelashes. [Accessed Nov 30, 2009]. .
    1. Chen CS, Wells J, Craig JE. Topical prostaglandin F2 analog induced poliosis. Am J Ophthalmol. 2004;137:965–966.
    1. Zaheri S, Hughes B. Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol. 2009 Nov 19; [Epub ahead of print]
    1. Ochoa BE, Sah D, Wang G, Stamper R, Price VH. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol. 2009;61:530–532.
    1. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol. 2000;118:718–719.
    1. Mehta JS, Raman J, Gupta N, Thoung D. Cutaneous latanoprost in the treatment of alopecia areata. Eye. 2003;17:444–446.
    1. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. J Am Acad Dermatol. 2009;60:705–706.
    1. Feletti F, Vincenzi C, Pazzaglia M, Tosti A. Periocular pigmentation associated with use of travoprost for the treatment of alopecia areata of the eyelashes. J Eur Acad Dermatol Venereol. 2007;21:421–423.
    1. Geng L, Hanson WR, Malkinson FD. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. Int J Radiat Biol. 1992;61:533–537.
    1. Hanson wR, Pelka AE, Nelson AK, Malkinson FD. Subcutaneous or topical administration of 16, 16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice. Int J Radiat Oncol Biol Phys. 1992;23:333–337.
    1. Malkinson FD, Geng L, Hanson WR. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. J Invest Dermatol. 1993;101:135S–137S.
    1. Cracknell KP, Grierson I, Hogg P, Appleton P, Pfeiffer N. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies. Exp Eye Res. 2003;77:721–730.
    1. Cracknell KP, Farnell DJ, Grierson I. Monte Carlo simulation of latanoprost induced iris darkening. Comput Methods Programs Biomed. 2007;87:93–103.
    1. Arranz-Marquez E, Teus MA. Effect of age on the development of a latanoprost-induced increase in iris pigmentation. Ophthalmology. 2007;114:1255–1258.
    1. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl 2):S129–S138.
    1. Stewart WC, Kolker AE, Stewart JA, et al. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135:314–320.
    1. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol. 2001;119:300–301.
    1. Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol. 2005;123:1541–1546.
    1. Centofanti M, Oddone F, Chimenti S, Tanga L, Citarella L, Manni G. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol. 2006;142:1059–1060.
    1. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574–577.
    1. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprostcan bimatoprost cause enophthalmos? Klin Monbl Augenheilkd. 2008;225:443–445.
    1. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24:302–307.
    1. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53:176–179.
    1. Packer M, Fine IH, Hoffman RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003;29:2242–2243.
    1. Parentin F. Granulomatous anterior uveitis associated with bimatoprost: a case report. Ocul Immunol Inflamm. 2003;11:67–71.
    1. Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668–672.
    1. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263.
    1. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998;126:37–41.
    1. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol. 2002;133:401–403.
    1. Kothari MT, Mehta BK, Asher NS, Kothari KJ. Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use. Indian J Ophthalmol. 2006;54:47–48.
    1. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127:602–604.
    1. Morales J, Shihab ZM, Brown SM, et al. Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol. 2001;132:114–116.
    1. Kaufman HE, Varnell ED, Thompson HW. Latanprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol. 1999;127:531–536.
    1. Gordon YJ, Yates KA, Mah FS, et al. The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models. J Ocul Pharmacol Ther. 2003;19:233–245.
    1. Hempstead N, Hempstead RW. Unilateral trichomegaly induced by bimatoprost ophthalmic solution. J Drugs Dermatol. 2004;3:571–572.
    1. Herane MI, Urbina F. Acquired trichomegaly of the eyelashes, and hypertrichosis induced by bimatoprost. J Eur Acad Dermatol Venereol. 2004;18:644–645.
    1. Hart J, Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol. 2004;137:756–757.
    1. Bearden W, Anderson R. Trichiasis associated with prostaglandin analog use. Ophthal Plast Reconstr Surg. 2004;20(4):320–322.
    1. Casson RJ, Selva D. Lash ptosis caused by latanoprost. Am J Ophthalmol. 2005;139:932–933.
    1. Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost-induced periocular skin changes in Caucasians. Ophthalmology. 2006;113:1961–1967.
    1. Herndon LW, Williams RD, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensice lipid use in African Americans. Am J Ophthalmol. 2003;135:713–715.
    1. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123–4128.
    1. Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004;137:966–968.
    1. Laibovitz RA, VanDenburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001;119:994–1000.
    1. Dubiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(Suppl 4):S353–S360.
    1. Lee YC. Abdominal cramp as an adverse effect of travoprost. Am J Ophthalmol. 2005;139:202–203.
    1. Mitra M, Chang B, James T. Drug points. Exacerbation of angina associated with latanoprost. BMJ. 2001;323:783.
    1. Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother. 1998;32:504–505.
    1. De Santis M, Lucchese A, Carducci B, et al. Latanoprost exposure in pregnancy. Am J Ophthalmol. 2004;138:305–306.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa